Welcome to our dedicated page for imac news (Ticker: imac), a resource for investors and traders seeking the latest updates and insights on imac stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect imac's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of imac's position in the market.
IMAC Holdings has successfully completed the second cohort of its Phase 1 clinical trial on umbilical cord-derived mesenchymal stem cells for treating bradykinesia in Parkinson’s patients. Five patients received medium concentration intravenous infusions, completed on February 15, 2022. Safety assessments will be ongoing for 30 days before the final cohort begins. The trial aims to ensure safety and tolerability for 15 participants across three dosage groups over a 12-month tracking period. This research supports IMAC's broader goal of innovative therapies for movement-restricting diseases.
IMAC Holdings, Inc. (Nasdaq: IMAC) has appointed Dr. Ben Lerner as Chief Operating Officer, effective February 21, 2022. Dr. Lerner brings over 20 years of healthcare and business experience, previously founding Maximized Living and leading multiple successful ventures. IMAC specializes in innovative orthopedic treatments and operates numerous outpatient clinics. The addition of Dr. Lerner is anticipated to enhance IMAC's leadership team and support its growth objectives. IMAC currently conducts clinical research for a stem cell therapy aimed at Parkinson's disease.
IMAC Holdings has successfully reduced its debt by repaying over $4.35 million in loans over the past 10 months, achieving more than 95% debt repayment. The firm now holds approximately $200,000 in remaining loans at a 5% interest rate, positioning itself for strategic growth in 2022. Both the CFO and CEO emphasized the importance of improved cash flow and earnings per share as they seek to enhance shareholder value. The company’s strong financial maneuvering is aimed at optimizing their operations in the face of ongoing challenges.
IMAC Holdings announces the launch of the BACK.co app, the first chiropractic app for mobile queue registration, aimed at enhancing patient engagement within its The Back Space pilot program at select Walmart locations. Services include chiropractic adjustments and muscle therapies priced at $25 per treatment or $65 monthly membership. The app offers a waitlist feature and educational content, reflecting IMAC's commitment to integrated spinal health solutions. This initiative is part of IMAC’s broader strategy to expand its customer base and service offerings.
IMAC Holdings has relocated the Ozzie Smith IMAC Regeneration Center in Webster Groves to a new 3,400-square foot facility in the Clock Building, motivated by an increase in patient demand. The center is now situated just one block from its previous location and reported over 9,000 patient visits in 2021. With a focus on regenerative orthopedic treatments without surgery or opioids, the clinic aims to expand treatment options. This move reflects the company's dedication to quality care and enhancing patient experiences in the St. Louis area.
IMAC Holdings, Inc. (Nasdaq: IMAC) announced that CEO Jeffrey Ervin will present at the H.C. Wainwright BIOCONNECT Virtual Conference from January 10-13, 2022. The on-demand presentation will be available starting at 7:00 a.m. ET on January 10. IMAC Holdings specializes in health and wellness services, focusing on orthopedic, sports medicine, and life science therapies. The company operates over 15 outpatient medical clinics and is conducting a Phase I clinical trial for a stem cell therapy targeting Parkinson’s disease.
IMAC Holdings announced its first The Back Space location has reached 100 active members. These centers, located within Walmart, offer affordable chiropractic and spinal care services, priced at $25 per treatment and $65 for a monthly membership. CEO Jeffrey Ervin expressed optimism about the membership model's growth potential. While the pilot program may not generate significant revenue soon, achieving this member milestone indicates strong service value and market demand. IMAC operates over 15 outpatient clinics and is conducting clinical trials for a stem cell therapy.
IMAC Holdings announces its participation in the Benzinga Global Small Cap Conference, scheduled for December 8-9, 2021. CEO Jeffrey Ervin will present on December 8 at 10:50 AM ET. The company focuses on innovative, non-surgical orthopedic treatments and operates health and wellness centers specializing in sports medicine and rehabilitation.
Investors can request one-on-one meetings with Mr. Ervin following the conference. More details about the conference registration can be found here.
IMAC Holdings has announced the promotion of Sandy Miller to Chief of Staff, following her role as Vice President of Clinical Development. This move is part of the company's strategy to accommodate its rapid growth in IMAC Regeneration Centers and The Back Space subsidiary. IMAC has also onboarded Norleidy Hernandez as Human Resources Director and Frank DeVito, III as Director of Sales. CEO Jeffrey Ervin noted that these appointments align with their expansion goals, including recent acquisitions and openings in Baton Rouge.
IMAC Holdings (Nasdaq: IMAC) reported its 3Q 2021 financial results, showing total revenue of $3.49 million, a slight increase from $3.48 million in 2020. Despite a 10% rise in patient visits to 43,451, the company faced a $1.7 million net loss, or $0.07 per share, compared to a $1.4 million loss last year. Cash reserves improved significantly to $11.2 million from $2.6 million. Operational challenges were noted due to the COVID-19 delta variant, impacting patient visits in western Kentucky. Strategic initiatives included the launch of The Back Space retail clinics.
FAQ
What is the market cap of imac (imac)?
